Pfizer's COVID-19 Meds Boost Sales: What's Next?

Pfizer's third-quarter earnings just came in, and guess what? They're way better than expected! The company's making a lot more money, thanks to a big demand for their COVID-19 treatments. Their best-selling drug, Paxlovid, brought in a whopping $2. 7 billion in the third quarter alone. This is a major win for Pfizer's CEO, Albert Bourla, who's been dealing with some trouble from an investor group called Starboard Value. This group thinks Pfizer could be doing even better and has been pushing for changes. Bourla agrees that there's room for improvement but thinks Pfizer is on the right track. He even says some of their recent business moves are already making a big difference.

Pfizer's sales jumped up by 31% compared to the same time last year, hitting $17. 7 billion. They even raised their sales goal for the whole year to between $61 billion and $64 billion. So, even with the activist investor's criticism, Pfizer seems to be doing pretty well.

Actions